The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Enteroaggregative Escherichia coli diarrhea in travelers: response to rifaximin therapy
Open accessAbstract
Background and aims We have recently shown that enteroaggregative Escherichia coli (EAEC) strains commonly cause travelers' diarrhea. The study was designed to determine whether U.S. travelers with EAEC diarrhea responded to rifaximin therapy.Methods In a multicenter placebo-controlled clinical trial of travelers' diarrhea without non-EAEC pathogens we evaluated 2 doses of rifaximin. EAEC was sought in stool samples in enrolled subjects by HEp-2 cell assay. Response to rifaximin (both groups combined) and placebo were evaluated in EAEC-positive and EAEC-negative patient groups.Results Compared with placebo, rifaximin shortened the postenrollment illness in travelers with EAEC diarrhea (median, 22 vs. 72 hours; P = 0.03). In subjects with EAEC-negative diarrhea, the median duration of post-treatment diarrhea was shorter with rifaximin (33 hours) than with placebo (52 hours), but this difference was not significantly different (P = 0.14).Conclusions Improvement of EAEC-mediated diarrhea with antibiotic treatment supports the pathogenicity of this organism in travelers to developing countries. The study provides information on the value of the poorly absorbed drug rifaximin in therapy of travelers' diarrhea.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Rifaximin shortened the duration of symptoms compared to placebo in a randomized controlled trial.
“It shortened the duration of symptoms compared to placebo in a randomized controlled trial [68]”
From Guideline for the Antibiotic Use in Acute Gastroenteritis (2019) · cites this paper as [68]
Citations
Cites
Association of Escherichia coli HEp-2 adherence patterns with type and duration of diarrhoea
Cravioto, A., Tello, A., Navarro, A., Ruiz, J., Villafán, H., Uribe, F., & Eslava, C. A. (1991) · The Lancet · doi:10.1016/0140-6736(91)90868-p · Cited by 318
Adachi, J. A., Jiang, Z., Mathewson, J. J., Verenkar, M. P., Thompson, S., Martinez‐Sandoval, F., Steffen, R. J., Ericsson, C. D., & DuPont, H. L. (2001) · Clinical Infectious Diseases · doi:10.1086/320756 · Cited by 215
Self-citationRisk and aetiology of diarrhoea at various tourist destinations
von Sonnenburg, F., Tornieporth, N., Waiyaki, P. G., Lowe, B. S., Peruski, L. F., DuPont, H. L., Mathewson, J. J., & Steffen, R. J. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02451-x · Cited by 209
Self-citationDuPont, H. L., Jiang, Z., Ericsson, C. D., Adachi, J. A., Mathewson, J. J., DuPont, M. W., Palazzini, E., Riopel, L., Ashley, D., & Martinez‐Sandoval, F. (2001) · Clinical Infectious Diseases · doi:10.1086/323814 · Cited by 205
Self-citationEpidemiology of diarrhea in travelers
Steffen, R. J. (1983) · JAMA · doi:10.1001/jama.249.9.1176 · Cited by 202
Self-citationA Newly Recognized Cause of Travelers' Diarrhea: Enteroadherent Escherichia coli
Mathewson, J. J., Johnson, P. C., DuPont, H. L., Morgan, D. R., Thornton, S., Wood, L., & Ericsson, C. D. (1985) · The Journal of Infectious Diseases · doi:10.1093/infdis/151.3.471 · Cited by 200
Self-citationCiprofloxacin or Trimethoprim-Sulfamethoxazole as Initial Therapy for Travelers' Diarrhea
Cd, E., JOHNSON, P. C., DuPont, H. L., Dr, M., Ja, B., & de la Cabada, F. J. (1987) · Annals of Internal Medicine · doi:10.7326/0003-4819-106-2-216 · Cited by 199
Self-citationGillis, J. C., & Brogden, R. N. (1995) · Drugs · doi:10.2165/00003495-199549030-00009 · Cited by 158
Stefano, M. D., Malservisi, Veneto, Ferrieri, & Corazza, G. R. (2000) · Alimentary Pharmacology & Therapeutics · doi:10.1046/j.1365-2036.2000.00751.x · Cited by 154
Therapy of Travelers' Diarrhea With Rifaximin on Various Continents
Steffen, R. J., Sack, D. A., Riopel, L., Jiang, Z., Stürchler, M., Ericsson, C. D., Lowe, B. S., Waiyaki, P. G., White, M., & DuPont, H. L. (2003) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2003.07283.x · Cited by 140
Self-citationVial, P., Mathewson, J. J., DuPont, H. L., Guers, L., & Levine, M. M. (1990) · Journal of Clinical Microbiology · doi:10.1128/jcm.28.5.882-885.1990 · Cited by 130
Self-citationJiang, Z., Greenberg, D. E., Nataro, J. P., Steffen, R. J., & DuPont, H. L. (2002) · Journal of Clinical Microbiology · doi:10.1128/jcm.40.11.4185-4190.2002 · Cited by 105
Self-citationMiglio, F., Valpiani, D., Rosellini, S. R., Ferrieri, A., & Canova, N. (1997) · Current Medical Research and Opinion · doi:10.1185/03007999709113333 · Cited by 99
Non‐absorbable antibiotics for managing intestinal gas production and gas‐related symptoms
Stefano, M. D., Strocchi, A., Malservisi, S., Veneto, G., Ferrieri, A., & Corazza, G. R. (2000) · Alimentary Pharmacology & Therapeutics · doi:10.1046/j.1365-2036.2000.00808.x · Cited by 95
Five versus three days of ofloxacin therapy for traveler's diarrhea: a placebo-controlled study
DuPont, H. L., Ericsson, C. D., Mathewson, J. J., & DuPont, M. W. (1992) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.36.1.87 · Cited by 92
Self-citationAdachi, J. A., Mathewson, J. J., Jiang, Z., Ericsson, C. D., & DuPont, H. L. (2002) · Annals of Internal Medicine · doi:10.7326/0003-4819-136-12-200206180-00009 · Cited by 87
Self-citationGlandt, M., Adachi, J. A., Mathewson, J. J., Jiang, Z., DiCesare, D., Ashley, D., Ericsson, C. D., & DuPont, H. L. (1999) · Clinical Infectious Diseases · doi:10.1086/520211 · Cited by 81
Self-citationWANKE, C. A., Gerrior, J., Blais, V., Mayer, H., & Acheson, D. W. K. (1998) · The Journal of Infectious Diseases · doi:10.1086/314443 · Cited by 81
Adachi, J. A., Ericsson, C. D., Jiang, Z., DuPont, M. W., Pallegar, S. R., & DuPont, H. L. (2002) · The Journal of Infectious Diseases · doi:10.1086/340419 · Cited by 78
Self-citationDuPont, H. L. (1992) · JAMA · doi:10.1001/jama.1992.03480140058033 · Cited by 70
Self-citationMathewson, J. J., Jiang, Z. D., Zumla, A. I., Chintu, C., Luo, N., Calamari, S., Genta, R. M., Steephen, A., Schwartz, P. E., & DuPont, H. L. (1995) · The Journal of Infectious Diseases · doi:10.1093/infdis/171.6.1636 · Cited by 56
Self-citationEvaluation of New Anti-Infective Drugs for the Treatment of Acute Infectious Diarrhea
DuPont, H. L., Cooperstock, M. S., Corrado, M. L., Fekety, R., & Murray, D. M. (1992) · Clinical Infectious Diseases · doi:10.1093/clind/15.supplement_1.s228 · Cited by 35
Self-citationDetection of Enteroaggregative Escherichia coli with Formalin-Preserved HEp-2 Cells
Miqdady, M. S., Jiang, Z., Nataro, J. P., & DuPont, H. L. (2002) · Journal of Clinical Microbiology · doi:10.1128/jcm.40.8.3066-3067.2002 · Cited by 25
Self-citationMathewson, J. J., Salameh, B. M., DuPont, H. L., Jiang, Z., Nelson, A., Arduino, R. C., Smith, M. A., & Masozera, N. (1998) · Clinical and Diagnostic Laboratory Immunology · doi:10.1128/cdli.5.1.87-90.1998 · Cited by 20
Self-citationDuPont, H. L. (1992) · JAMA · doi:10.1001/jama.267.14.1932 · Cited by 19
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
Guarino, A., Ashkenazi, S., Gendrel, D., Lo Vecchio, A., Shamir, R., & Szajewska, H. (2014) · Journal of Pediatric Gastroenterology and Nutrition · doi:10.1097/mpg.0000000000000375 · Cited by 935
ACG Clinical Guideline: Diagnosis, Treatment, and Prevention of Acute Diarrheal Infections in Adults
Riddle, M. S., DuPont, H. L., & Connor, B. A. (2016) · American Journal of Gastroenterology · doi:10.1038/ajg.2016.126 · Cited by 435
Self-citationRossignol, J., Abu‐Zekry, M., Hussein, A. K., & Santoro, M. (2006) · The Lancet · doi:10.1016/s0140-6736(06)68852-1 · Cited by 193
Rossignol, J., & El-Gohary, Y. (2006) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2006.03128.x · Cited by 180
Al-Abri, S., Beeching, N. J., & Nye, F. J. (2005) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(05)70139-0 · Cited by 170
Guarino, A., Ashkenazi, S., Gendrel, D., Vecchio, A. L., Shamir, R., & Szajewska, H. (2015) · PubMed · Cited by 156
A review of an emerging enteric pathogen: enteroaggregative Escherichia coli
Huang, D. B., Mohanty, A., DuPont, H. L., Okhuysen, P. C., & Chiang, T. (2006) · Journal of Medical Microbiology · doi:10.1099/jmm.0.46674-0 · Cited by 155
Self-citationPrevention and Self-Treatment of Traveler's Diarrhea
Diemert, D. J. (2006) · Clinical Microbiology Reviews · doi:10.1128/cmr.00052-05 · Cited by 127
Enteroaggregative Escherichia coli : An Emerging Enteric Food Borne Pathogen
Kaur, P., Chakraborti, A., & Asea, A. A. A. (2010) · Interdisciplinary Perspectives on Infectious Diseases · doi:10.1155/2010/254159 · Cited by 124
Rifaximin: a nonabsorbable rifamycin antibiotic for use in nonsystemic gastrointestinal infections
Gerard, L., Garey, K. W., & DuPont, H. L. (2005) · Expert Review of Anti-infective Therapy · doi:10.1586/14787210.3.2.201 · Cited by 116
Self-citationBile Acids Improve the Antimicrobial Effect of Rifaximin
Darkoh, C., Lichtenberger, L. M., Ajami, N. J., Dial, E. J., Jiang, Z., & DuPont, H. L. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00161-10 · Cited by 102
Self-citationBrown, E. L., Xue, Q., Jiang, Z., Xu, Y., & DuPont, H. L. (2009) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00691-09 · Cited by 96
Self-citationGarey, K. W., Jiang, Z., Bellard, A., & DuPont, H. L. (2008) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0b013e31814a4e97 · Cited by 90
Self-citationEpidemiology, Etiology and Pathophysiology of Traveler’s Diarrhea
Gascón, J. (2006) · Digestion · doi:10.1159/000089785 · Cited by 81
Ouyang‐Latimer, J., Jafri, S. H. R., VanTassel, A., Jiang, Z., Gurleen, K., Rodriguez, S., Nandy, R. K., Ramamurthy, T., Chatterjee, S., McKenzie, R., et al. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00739-10 · Cited by 73
Self-citationEnteroaggregative Escherichia coli: An emerging pathogen in children
Huang, D. B., & DuPont, H. L. (2004) · Seminars in Pediatric Infectious Diseases · doi:10.1053/j.spid.2004.07.008 · Cited by 58
Self-citationGuideline for the Antibiotic Use in Acute Gastroenteritis
Kim, Y. J., Park, K.-H., Park, D.-A., Park, J., Bang, B. W., Lee, S. S., Lee, E. J., Lee, H.-J., Hong, S. K., & Kim, Y. R. (2019) · Infection & Chemotherapy · doi:10.3947/ic.2019.51.2.217 · Cited by 46
“It shortened the duration of symptoms compared to placebo in a randomized controlled trial [68], and its effects were comparable to those of fluoroquinolones [69, 70].”
ResultShamir, E. R., Warthan, M., Brown, S. P., Nataro, J. P., Guerrant, R. L., & Hoffman, P. S. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01279-09 · Cited by 45
Biologic properties and clinical uses of rifaximin
DuPont, H. L. (2011) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2011.546347 · Cited by 43
Self-citationMyoviridae phage PDX kills enteroaggregative Escherichia coli without human microbiome dysbiosis
Cepko, L. C. S., Garling, E. E., Dinsdale, M. J., Scott, W. P., Bandy, L., Nice, T. J., Faber-Hammond, J. J., & Mellies, J. L. (2020) · Journal of Medical Microbiology · doi:10.1099/jmm.0.001162 · Cited by 39
Robins, G. W., & Wellington, K. (2005) · Drugs · doi:10.2165/00003495-200565120-00011 · Cited by 33
Riddle, M. S., Martin, G. J., Murray, C. K., Burgess, T. H., Connor, P., Mancuso, J. D., Schnaubelt, E. R., Ballard, T. P., Fraser, J., & Tribble, D. R. (2017) · Military Medicine · doi:10.7205/milmed-d-17-00077 · Cited by 32
Modgil, V., Mahindroo, J., Narayan, C., Kalia, M., Yousuf, M., Shahi, V., Koundal, M., Chaudhary, P., Jain, R., Sandha, K. S., et al. (2020) · PLoS neglected tropical diseases · doi:10.1371/journal.pntd.0008769 · Cited by 28
Rifaximin for the treatment of acute infectious diarrhea
Hong, K. S., & Kim, J. S. (2011) · Therapeutic Advances in Gastroenterology · doi:10.1177/1756283x11398734 · Cited by 27
Tokuda, K., Nishi, J., Imuta, N., Fujiyama, R., Kamenosono, A., Manago, K., & Kawano, Y. (2010) · Microbiology and Immunology · doi:10.1111/j.1348-0421.2010.00210.x · Cited by 27
LAYER, P., & Andresen, V. (2010) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2010.04296.x · Cited by 27
Poorly Absorbed Antibiotics for the Treatment of Traveler' Diarrhea
Taylor, D. N. (2005) · Clinical Infectious Diseases · doi:10.1086/432953 · Cited by 26
Shiga Toxin–Producing Escherichia coli O104:H4
Jandhyala, D. M., Vanguri, V. K., Boll, E. J., Lai, Y., McCormick, B. A., & Leong, J. M. (2013) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2013.05.002 · Cited by 25
Rifaximin in the Treatment of Infectious Diarrhea
Ericsson, C. D., & DuPont, H. L. (2005) · Chemotherapy · doi:10.1159/000081992 · Cited by 22
Self-citationRifaximin-Mediated Changes to the Epithelial Cell Proteome: 2-D Gel Analysis
Schrodt, C. A., McHugh, E. E., Gawinowicz, M. A., DuPont, H. L., & Brown, E. L. (2013) · PLoS ONE · doi:10.1371/journal.pone.0068550 · Cited by 21
Self-citationCurrent concepts in travelersʼ diarrhea: epidemiology, antimicrobial resistance and treatment
Okhuysen, P. C. (2005) · Current Opinion in Infectious Diseases · doi:10.1097/01.qco.0000185987.02878.6e · Cited by 20
Prevention and Treatment of Traveler’s Diarrhea
Castelli, F., Saleri, N., Tomasoni, L. R., & Carosi, G. (2006) · Digestion · doi:10.1159/000089786 · Cited by 20
Enteroaggregative Escherichia coli : A review of trends, diagnosis, and treatment
Cennimo, D. J., Koo, H. L., Jamal, M. A., Huang, D. B., & Chiang, T. (2007) · Infections in medicine · Cited by 19
Enteroaggregative Escherichia coli an emergent pathogen with different virulence properties.
Villaseca, J. M., Hernández, U., Sainz-Espuñes, T., Rosario, C., & Eslava, C. A. (2005) · PubMed · Cited by 19
Rifaximin: a nonsystemic rifamycin antibiotic for gastrointestinal infections
Cottreau, J. M., Baker, S. F., DuPont, H. L., & Garey, K. W. (2010) · Expert Review of Anti-infective Therapy · doi:10.1586/eri.10.58 · Cited by 18
Self-citationGuarino, A., Albano, F., Ashkenazi, S., Hoekstra, J. H., Shamir, R., Chmielewska, A., Hartman, C., Ashkenazi‐Hoffnung, L., Lo, A., Patro-Gołąb, B., et al. (2008) · Cited by 14
Rifaximin: A New Treatment for Travelers' Diarrhea
Pakyz, A. L. (2004) · Annals of Pharmacotherapy · doi:10.1345/aph.1e407 · Cited by 10
Infectious Diarrhea from Wilderness and Foreign Travel
Adachi, J. A., Backer, H., & DuPont, H. L. (2007) · Elsevier eBooks · doi:10.1016/b978-0-323-03228-5.50067-7 · Cited by 10
Self-citationEnteroaggregative Escherichia coli (EAEC)
Nederveen, V. V., & Melton‐Celsa, A. R. (2025) · EcoSal Plus · doi:10.1128/ecosalplus.esp-0011-2024 · Cited by 14
Enteroaggregative Escherichia coli
Boisen, N., Krogfelt, K. A., & Nataro, J. P. (2013) · Elsevier eBooks · doi:10.1016/b978-0-12-397048-0.00008-5 · Cited by 9
Nederveen, V. V., & Melton‐Celsa, A. R. (2024) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2024.1379206 · Cited by 7
Utility of the Nonabsorbed (<0.4%) Antibiotic Rifaximin in Gastroenterology and Hepatology.
Su, C. G., Aberra, F. N., & Lichtenstein, G. R. (2006) · PubMed Central · Cited by 7
Rifamycin SV MMX for the treatment of traveler’s diarrhea
Lin, S., Lin, C., & Yang, J. (2017) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2017.1353079 · Cited by 6
Inhibition of enteroaggregative Escherichia coli cell adhesion in-vitro by designed peptides
Gupta, D., Sarkar, S., Sharma, M., Thapa, B. R., & Chakraborti, A. (2016) · Microbial Pathogenesis · doi:10.1016/j.micpath.2016.06.014 · Cited by 5
Travelers' Diarrhea, New Insights
Okhuysen, P. C. (2007) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0b013e31802fb4c7 · Cited by 3
A Case of Acute Abdomen Caused by Enteroaggregative Escherichia coli
Mohty, K. M., Kay, R., Safavi, A., Memeh, K., & McClenathan, J. H. (2017) · Surgical Infections Case Reports · doi:10.1089/crsi.2017.0002 · Cited by 2
New Perspectives on Enteric Pathogenic Bacteria Bacterium Escherichia coli
ALjohni, A. R. S., Almotiri, T. R., Alhazmy, T. I., Alqouzi, G. K. S., & Mhmodi, F. O. A. (2021) · ACTA SCIENTIFIC MICROBIOLOGY · doi:10.31080/asmi.2021.04.0974 · Cited by 2
GIH Clinical Research Update: 2004–2005
Camilleri, M. (2005) · Clinical Gastroenterology and Hepatology · doi:10.1016/s1542-3565(05)00758-5 · Cited by 1
DuPont, H. L., Estrada-Garcia, M. T., & Jiang, Z. (2009) · Springer eBooks · doi:10.1007/978-0-387-09843-2_15 · Cited by 1
Self-citation▼Rifaximin for the treatment of travellers' diarrhoea?
(2013) · Drug and Therapeutics Bulletin · doi:10.1136/dtb.2013.1.0156 · Cited by 1
Perrone, V., Usala, M., Veronesi, C., Cappuccilli, M. L., & Esposti, L. D. (2025) · Medicina · doi:10.3390/medicina61020221 · Cited by 1
Enteric Escherichia coli Infections
Steiner, T. S., Thielman, N. M., & Guerrant, R. L. (2011) · Elsevier eBooks · doi:10.1016/b978-0-7020-3935-5.00015-x · Cited by 1
Escherichia coli en pathologie digestive
Germani, Y., Bouguénec, C. L., & Sansonetti, P. J. (2008) · EMC-Maladies infectieuses/Encyclopédie médico-chirurgicale. Maladies infectieuses · doi:10.1016/s1166-8598(08)45776-9
Investigating enteroaggregative Escherichia coli virulence factors in human intestinal infection
Ellis, S. (2018) · UEA Digital Repository (University of East Anglia)
Myoviridae Phage PDX Kills Enteroaggregative Escherichia coli without Human Microbiome DysbiosisPreprint
Cepko, L. C. S., Garling, E. E., Dinsdale, M. J., Scott, W. P., Bandy, L., Nice, T. J., Faber-Hammond, J. J., & Mellies, J. L. (2018) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/385104
Metadata
- Authors
- Infante, R. M., Ericsson, C. D., Jiang, Z.-D., Ke, S., Steffen, R., Riopel, L., Sack, D. A., & Du>Pont, H. L.
- Affiliations
- The University of Texas Health Science Center at Houston (US)
- Venue
- Clinical Gastroenterology and Hepatology
- Publisher
- Elsevier BV
- Published
- 2004-02
- Volume
- 2
- Issue
- 2
- Pages
- 135-138
- ISSN
- 1542-3565 (ISSN-L)
- OpenAlex
- W2165399037
- Cited by
- 55
- References
- 24
- Citations by year
- 2025: 2 · 2024: 1 · 2021: 1 · 2020: 2 · 2019: 1 · 2018: 2 · 2017: 3 · 2016: 2 · 2015: 1 · 2014: 1 · 2013: 4
- FWCI
- 6.79
- Type
- journal article
- Language
- en
- Open access
- green
- doi.org
- Locations
- Clinical Gastroenterology and Hepatology (publishedVersion)
- PubMed (publishedVersion)
- Zurich Open Repository and Archive (University of Zurich) (acceptedVersion)
- Zurich Open Repository and Archive (University of Zurich) (submittedVersion)
- Zurich Open Repository and Archive (University of Zurich)
- Topics
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Travel-related health issues
- Life Sciences › Immunology and Microbiology › Microbiology › Escherichia coli research studies
- Life Sciences › Agricultural and Biological Sciences › Food Science › Salmonella and Campylobacter epidemiology
- Keywords
- enteroaggregative Escherichia coli, traveler's diarrhea, rifaximin, antibiotic therapy, pathogenicity, diarrhea duration, developing countries
- MeSH terms
- Rifaximin, Anti-Infective Agents, Diarrhea, Escherichia coli, Escherichia coli Infections, Humans, Rifamycins, Travel, Treatment Outcome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
